Phage survival: The biodegradability of M13 phage display library in vitro

被引:12
作者
Tothova, L'ubomira [1 ]
Babickova, Janka [1 ]
Celec, Peter [1 ,2 ,3 ]
机构
[1] Comenius Univ, Inst Mol Biomed, Bratislava 81108, Slovakia
[2] Comenius Univ, Dept Mol Biol, Bratislava 81108, Slovakia
[3] Comenius Univ, Inst Pathophysiol, Bratislava 81108, Slovakia
关键词
bacteriophage; viability; tissue homogenates; body fluids; ex vivo; PROTEIN-PROTEIN INTERACTIONS; HUMAN SALIVA; PEPTIDE LIBRARIES; BACTERIOPHAGE; THERAPY; MICE; IDENTIFICATION; INFECTIONS; ANTIBODIES; BARRIER;
D O I
10.1002/bab.1050
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Administration of bacteriophages is used for phage therapy modulation of gut microbiome or for in vivo phage display. The aim of the study was to analyze the survival of M13 phage in different body fluids and tissues in vitro. The survival of M13 phage was measured in vitro in human blood, saliva, urine, artificial gastric juice (AGJ), and mouse homogenates of stomach, jejunum, and colon after defined time points (5, 15, or 45 Min). The plates were inspected after overnight incubation and the plaques were counted. No phage was recovered after 5 Min of incubation with AGJ. In urine, the phage survival was decreased by 44% after 5 Min of incubation (P = 0.004). In saliva, the recovered titer was decreased by 33% and 88% (P < 0.05) after 15 and 45 Min, respectively. Phage coincubation with jejunum homogenate led to significant decrease of phage titer by 72% (P < 0.01) after 15 Min and by 99% (P < 0.001) after 45 Min. Decreased survival of M13 phage depending on time of incubation was proved under several in vitro conditions, with low pH in the AGJ having the most detrimental effect on phage survival. Phage pharmacokinetics described in vitro might have applications for the use of bacteriophages in vivo.
引用
收藏
页码:490 / 494
页数:5
相关论文
共 32 条
[1]  
[Anonymous], BMJ
[2]   Bacteriophage isolation from human saliva [J].
Bachrach, G ;
Leizerovici-Zigmond, M ;
Zlotkin, A ;
Naor, R ;
Steinberg, D .
LETTERS IN APPLIED MICROBIOLOGY, 2003, 36 (01) :50-53
[3]  
BERGEY EJ, 1994, J ACQ IMMUN DEF SYND, V7, P995
[4]   Phage display peptide probes for imaging early response to bevacizumab treatment [J].
Cao, Qizhen ;
Liu, Shuanglong ;
Niu, Gang ;
Chen, Kai ;
Yan, Yongjun ;
Liu, Zhaofei ;
Chen, Xiaoyuan .
AMINO ACIDS, 2011, 41 (05) :1103-1112
[5]   Survival of enteric bacteria and coliphage MS2 in pure human urine [J].
Chandran, A. ;
Pradhan, S. K. ;
Heinonen-Tanski, H. .
JOURNAL OF APPLIED MICROBIOLOGY, 2009, 107 (05) :1651-1657
[6]   In vitro and in vivo bacteriolytic activities of Escherichia coli phages:: Implications for phage therapy [J].
Chibani-Chennoufi, S ;
Sidoti, J ;
Bruttin, A ;
Kutter, E ;
Sarker, S ;
Brüssow, H .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (07) :2558-2569
[7]   Bacteriophages and biotechnology: vaccines, gene therapy and antibacterials [J].
Clark, JR ;
March, JB .
TRENDS IN BIOTECHNOLOGY, 2006, 24 (05) :212-218
[8]  
Dinh Q, 1996, J IMMUNOL, V157, P732
[9]   Identification of peptide sequences that induce the transport of phage across the gastrointestinal mucosal barrier [J].
Duerr, DM ;
White, SJ ;
Schluesener, HJ .
JOURNAL OF VIROLOGICAL METHODS, 2004, 116 (02) :177-180
[10]   Bacteriophages and their application in food safety [J].
Garcia, P. ;
Martinez, B. ;
Obeso, J. M. ;
Rodriguez, A. .
LETTERS IN APPLIED MICROBIOLOGY, 2008, 47 (06) :479-485